Gilead Sciences Inc GILD

$156.04 -1.15 (-0.73%)

Valuation

Market cap
193,482,560,000
Revenue TTM
$29,443,000,000
Net income TTM
$8,510,000,000
PE ratio
0.00
Forward PE
—
Profit margin
28.90%
Debt to equity
2.23

Trading

Volume
6,070,900
Avg volume
5,725,952
Day's range
$155.76 – $157.65
Shares out
1,239,955,000
Stochastic %K
66%
Beta
0.31
Analysts
Strong Sell
Price target
$158.90

Price

Company profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary bi...

Show more

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
650 574 3000
Website
https://www.gilead.com
Address
333 Lakeside Drive, Foster City, United States

Latest news

Stocktwits

RockyTSTH Oct 25, 8:34 PM
OPTION WATCHLIST 10/25/2026 $TEAM- Stock in a steady uptrend and breaking out post channel breakout. Looking for calls above $230 for a move towards $240 and $250. Stock got multiple price target upgrades. $TSM- Stock at support zone from $400 to $410. Stock currently in the zone. Looking for calls above $420 for a move towards $435 and $450. Puts below $400. $ZETA- Stock moving higher with multiple price target upgrades from analysts. Stock has been in the zone for sometime. Looking for $34.50 for a move towards $36 and bigger breakout above it. $CVX- Stock breaking out and hitting all time highs on friday. Oil stocks are in high demand. Looking for calls above $235 for a move towards $250 and higher. $GILD - Stock making a Cup shaped pattern on the daily. Looking for a possible breakout soon. Looking for breakout above $160 for a move towards $180 and higher.
1 replies
KryptonResearch14 Oct 25, 1:07 PM
$GILD Gilead reports Q3 Thursday after the close. Zacks consensus sits at 2.16 dollars a share on 7.81 billion dollars of revenue, up just 0.6% from a year ago. That is basically flat vs Q2's actual 7.80 billion too, even though HIV sales grew 12% in Q2 to 5.69 billion and management raised full-year HIV growth guidance to 9% to 10%. Veklury getting guided down and cell therapy guided to a mid-teens decline are doing the offsetting. Yeztugo did 232 million dollars in Q2, up 40% sequentially, and management maintained a roughly 1 billion dollar full-year target for it. The ramp has to keep steepening from here.
1 replies
TopOptionAlert Oct 25, 10:45 AM
$GILD OCT30 160C · actionable here Zone: $154.95 to $157.13 Invalidation: close under $153 Objectives: $160.51, then $170 The math: up 2.9% to the first objective and 8.9% to the second, against 1.9% risk on the invalidation, better than 4 to 1 to the second. This is a swing setup, and the picture is plain. Gilead closed Friday at 156 dollars and 4 cents, a short walk from its 52 week high of 160 dollars and 51 cents, after the company agreed to pay 1.275 billion dollars upfront for an oral bowel disease program that fills a real hole in its pipeline. With earnings set for Thursday October 29 after the close, this October 30 call gives the story room to run through the report instead of expiring before it. If the stock climbs over its old high, the road toward 170 opens in a plain and simple way, and a close under 153 tells you the idea is wrong. P.S. Jefferies lifted its target to 185 this week, a long way above the Friday close.
0 replies
LangLeverage Oct 24, 6:14 PM
$GILD hope everyone involved gets to see their hard work lead somewhere good
0 replies
TopOptionAlert Oct 24, 12:53 PM
$GILD NOV20 160C · still actionable Zone: $154.95 to $157.13 Invalidation: close under $153 Objectives: $160.51, then $170 The math: up 2.9% to the first objective and 8.9% to the second, against 1.9% risk on the invalidation, better than 4 to 1 to the second. Dear friend, picture a steady workshop that just spent 1.275 billion dollars to buy a new tool for gut disease, because it knows exactly what piece its bench was missing. Gilead closed Friday at 156 dollars and 4 cents, holding above the 153 dollar low from October 22, with the third quarter report landing October 29 and this November 20 call running past that report, so you are positioned before the answer instead of chasing after it. This is a swing back toward the 160 dollar and 51 cent high from October 15, with a clear line at 153 dollars that says the idea is wrong if it closes under it. P.S. Watch 160 dollars and 51 cents first, because a move over it puts Gilead at a fresh high for the year.
0 replies
StocktwitsNews Oct 24, 12:01 AM
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week $GILD $ZYME $RHHBY https://stocktwits.com/news/equity/markets/stocktwits-biotech-dealmaker-gilead-and-roche-double-down-on-early-stage-assets-over-full-buyouts-this-week/cZUGPL8RBUe
1 replies
TopOptionAlert Oct 23, 5:34 PM
$GILD OCT30 160C · update Called at $153.26 on Oct 21, now $157.05 (+2.5%). The trade is working, with objectives at $160.51, then $170, and the invalidation at $150. P.S. Watch the run into earnings on Oct 29, because the report is the spark that can carry it to the first objective.
0 replies
Adam_1916 Oct 23, 3:11 PM
$GILD gets an oral IL23 on the cheap, adding it alongside a4b7 in the IBD pipeline… …only one more piece to complete the armamentareum and all but guarantee *complete* dominance of the oral IBD market. Let’s see!
2 replies